The Big Short: Drug Shortage Impact & Innovations for Hospitalists-Slides

Slides

Pdf Summary

“The Big Short: Drug Shortage Impacts, Insights & Innovations” presents a comprehensive overview of recent critical drug shortages, underlying causes, their impacts on healthcare, and strategies for management and advocacy.<br /><br />Key drug shortages discussed include amoxicillin (2022-2023), RSV vaccines, chemotherapy agents (notably cisplatin and carboplatin), and benzodiazepines. The amoxicillin shortage led to increased use of cefdinir and amoxicillin-clavulanate without worsening short-term outcomes but did not promote antibiotic deprescribing or sustained prescribing changes. The RSV vaccine shortage resulted from unprecedented demand amid new FDA approvals and changing CDC recommendations, complicated by supply limitations, notably by Sanofi. Chemotherapy shortages have caused delays in clinical trials, rationing of key drugs, use of inferior alternatives, and increased mortality, particularly affecting breast, colon, head & neck cancers. Intravenous benzodiazepine shortages triggered adjustments in treatment protocols for alcohol withdrawal syndrome.<br /><br />Insights focus on the generic sterile injectable (GSI) drug market, which is small and highly specialized. Supply chain fragility includes factors such as limited manufacturers (often single-source), stringent quality requirements, transportation issues, and the dominant role of group purchasing organizations (GPOs) and wholesalers that influence hospital purchasing yet not always aligned with supply stability. Drug shortages generate significant hidden costs for hospitals, including increased labor and expenditures on alternative drugs.<br /><br />Innovations highlighted include the Mayo Clinic’s Medication Shortage Management Oversight Subcommittee fostering proactive, multi-disciplinary approaches; development of benzodiazepine-sparing alcohol withdrawal order sets demonstrating improved outcomes; and conservation strategies for chemotherapy drugs, such as dose rounding and batching patient schedules.<br /><br />The presentation concludes with a call to action, emphasizing that drug shortages can catalyze meaningful change. Proposed policy solutions include supporting manufacturing upgrades, incentivizing realigned hospital purchasing, and creating government-funded inventory buffers. Engaging the physician community constructively in advocacy and leveraging legislative initiatives—like the MAPS Act and Pediatric Drug Supply Bills—are essential steps to ensure sustainable drug supplies and improved patient care continuity.

Keywords

drug shortages

amoxicillin shortage

RSV vaccine shortage

chemotherapy drug shortage

benzodiazepine shortage

generic sterile injectable market

supply chain fragility

drug shortage management

medication shortage innovations

drug shortage policy solutions